MedTrace Logo

REducing Diabetic MacrovascUlar Complications DuE to Peripheral Arterial Disease- REDUCE-PAD

NCT05912218 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2024-11-21

No results posted yet for this study

Summary

This is a Phase IIa, multi-centre study conducted at 3 sites in Singapore (SGH and NUHS, KTPH). 70 patients with diabetes mellitus (DM) and peripheral arterial disease (PAD) will be randomised in a ratio 1:1 to receive normal saline control or MEDI6570 400mg by monthly subcutaneous injection for 9 months.

Conditions

  • Diabetes Mellitus, Type 2
  • Peripheral Arterial Disease

Interventions

BIOLOGICAL

MEI6570

Saline Control

Sponsors & Collaborators

  • Singapore General Hospital

    collaborator OTHER

  • Khoo Teck Puat Hospital

    collaborator OTHER

  • National University Health System, Singapore

    collaborator OTHER

  • National Heart Centre Singapore

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-02
Primary Completion
2025-09-01
Completion
2025-12-01
FDA Drug
Yes

Countries

  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05912218 on ClinicalTrials.gov